| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| GSK | GlaxoSmithKline PLC | $39.21 | $97.25B | N/A |
3 High-Yield Dividend Aristocrat Stocks
https://www.fool.com/investing/2017/08/28/3-high-yield-dividend-aristocrat-stocks.aspx?source=iedfolrf0000001
Aug 28, 2017 - These three high-yield dividend stocks may be worth checking out right now.
23
Stocks making the biggest moves premarket: BLK, DAL, GE, BBBY, WMT, GSK, LMT & more
https://www.cnbc.com/2018/04/12/stocks-making-the-biggest-moves-premarket-blk-dal-ge-bbby-wmt-gsk-lmt-more.html
Apr 12, 2018 - Names on the move ahead of the open.
11
3 Beaten-Up Biotech Stocks: Are They Bargains?
https://www.fool.com/investing/2017/08/14/3-beaten-up-biotech-stocks-are-they-bargains.aspx?source=iedfolrf0000001
Aug 14, 2017 - It's been a pretty good year for biotech, but these three stocks have tumbled. Is the pessimism overblown?
8
3 High-Yield Healthcare Stocks
https://www.fool.com/investing/2017/08/10/3-high-yield-healthcare-stocks.aspx?source=iedfolrf0000001
Aug 10, 2017 - Looking for income from the healthcare sector? Here's why you should check out GlaxoSmithKline, Pfizer, and CVS Health.
8
Pfizer consumer health deal will help fuel investments in pharma, vaccines, says GSK CEO
https://www.cnbc.com/2018/12/19/gsk-ceo-emma-walmsley-on-pfizer-consumer-health-deal-.html
Dec 19, 2018 - Pfizer and GSK will combine their consumer health units and plan to spin the joint venture off.
7
Space Quarterly: Triangle office market hits new high – but there’s a catch
http://feeds.bizjournals.com/~r/industry_20/~3/6YMj3TihKeU/space-quarterlytriangle-office-market-hits-new.html
Aug 09, 2017 - 
The Triangle region’s office market had an unusually high volume of new space absorption in the second quarter of 2017.
5
The Triangle region’s office market had an unusually high volume of new space absorption in the second quarter of 2017.
5
3 Stocks With iRobot-Like Return Potential
https://www.fool.com/investing/2017/05/26/3-stocks-with-irobot-like-return-potential.aspx?source=iedfolrf0000001
May 26, 2017 - Here are three stocks that stand a chance to double -- and then some -- over the next year or so.
5
GSK's shingles vaccine gets positive FDA recommendation
http://feeds.bizjournals.com/~r/industry_6/~3/A-YSWlNZ7dY/gsks-shingles-vaccine-gets-positive-fda.html
Sep 13, 2017 - 
A Food and Drug Administration advisory panel voted unanimously Wednesday to recommend approval for GlaxoSmithKline's new drug candidate Shingrix, a vaccine for preventing shingles in adults age 50 and older.
The vote by the Vaccines and Related Biological Products Advisory Committee was 11-0 in support of the biologics license application submitted by GlaxoSmithKline last October. The committee's recommendation is nonbinding, but the FDA typically follows the advice of its advisory panels.
If…
5
A Food and Drug Administration advisory panel voted unanimously Wednesday to recommend approval for GlaxoSmithKline's new drug candidate Shingrix, a vaccine for preventing shingles in adults age 50 and older.
The vote by the Vaccines and Related Biological Products Advisory Committee was 11-0 in support of the biologics license application submitted by GlaxoSmithKline last October. The committee's recommendation is nonbinding, but the FDA typically follows the advice of its advisory panels.
If…
5
Pharma Industry Outlook - February/March 2017
http://www.zacks.com/commentary/104804/pharma-industry-outlook-february-march-2017?cid=CS-ZC--104804
Feb 27, 2017 - Pharma Industry Outlook - February/March 2017
4
Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
https://www.fool.com/investing/2017/09/13/regenerons-dupixent-takes-another-step-toward-bloc.aspx?source=iedfolrf0000001
Sep 13, 2017 - Dupixent's phase 3 trials in asthma were a success, clearing the way to an FDA filing this year in this multibillion-dollar indication.
4
Page 1>